Ramucirumab monotherapy or in combination with paclitaxel is a second-line treatment option for patients with advanced gastric or gastroesophageal junction adenocarcinoma (with or without hepatocyte growth factor receptor [MET]-positive tumors) [5,6]. The gene discussed is MET; the disease is gastroesophageal junction adenocarcinoma.